With 2.4 million shares changed hands, the volume of the stock remained heavier than its average volume of 68090.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5 whereas the lowest price it dropped to was $3.35. The 52-week range on CRIS shows that it touched its highest point at $17.49 and its lowest point at $2.86 during that stretch. It currently has a 1-year price target of $21.00. Beta for the stock currently stands at 3.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRIS was up-trending over the past week, with a rise of 33.75%, but this was down by -4.07% over a month. Three-month performance dropped to -17.51% while six-month performance fell -32.16%. The stock lost -65.94% in the past year, while it has gained 38.56% so far this year. A look at the trailing 12-month EPS for CRIS yields -7.81 with Next year EPS estimates of -4.38. For the next quarter, that number is -1.34. This implies an EPS growth rate of 22.88% for this year and 36.61% for next year.
Float and Shares Shorts:
At present, 8.47 million CRIS shares are outstanding with a float of 7.77 million shares on hand for trading. On 2024-10-31, short shares totaled 0.14 million, which was 228.00000000000003 higher than short shares on 1727654400. In addition to Mr. James E. Dentzer as the firm’s President, CEO, Secretary, Treasurer & Director, Ms. Diantha Duvall CPA, M.B.A. serves as its CFO and Principal Financial & Accounting Officer.
Institutional Ownership:
Through their ownership of 0.24365999 of CRIS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CRIS reported revenue of $2931000.0 and operating income of -$10567000.0. The EBITDA in the recently reported quarter was -$10506000.0 and diluted EPS was -$1.7.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRIS since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRIS analysts setting a high price target of 26.0 and a low target of 18.0, the average target price over the next 12 months is 21.0. Based on these targets, CRIS could surge 513.21% to reach the target high and rise by 324.53% to reach the target low. Reaching the average price target will result in a growth of 395.28% from current levels.
Analysts have provided yearly estimates in a range of -$6.55091 being high and -$7.46319 being low. For CRIS, this leads to a yearly average estimate of -$6.91.
